Microneedle-Mediated Allergen-Specific Immunotherapy for the Treatment of Airway Allergy in Mice

Akhilesh Kumar Shakya, Chang Hyun Lee, Harvinder Singh Gill

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Subcutaneous allergen-specific immunotherapy (SCIT) qualifies as a promising approach for the permanent cure of IgE-mediated airway allergies, which can often manifest into allergic rhinitis and other allergic respiratory diseases. SCIT entails repeated administration of a high allergen dose into the subcutaneous (sc) region using a hypodermic needle for many (3-5) years, which is inconvenient and painful and reduces patient compliance. To overcome these limitations, we hypothesized that microneedles (MNs), which are minimally invasive and painless, could provide a novel approach for allergen desensitization by depositing the allergen into the superficial layers of the skin. To test this hypothesis, we compared MNs and SCIT for allergen desensitization in a mouse model of ovalbumin (Ova)-induced airway allergy. Mice were first made allergic to Ova and then treated with MNs coated with Ova (with or without CpG as an adjuvant) or via SCIT-Ova + alum (subcutaneous Ova + alum injections) for comparison. Treatment with coated MNs significantly induced Ova-specific serum IgG antibodies in a manner comparable to SCIT-Ova + alum-treated group. To test the efficacy against allergen challenge, treated mice were challenged with Ova via the nasal route. Coated MNs with Ova and CpG (MN-Ova + CpG) considerably suppressed the airway inflammation in allergic mice, evidenced by downregulation of proinflammatory cytokines (IL-5 and IL-13), upregulation of anti-inflammatory cytokine IL-10, and activation of Ova-specific immune response in bronchoalveolar (BAL) fluid. The therapeutic capacity of MN-based allergy treatment was further validated by the reduction in eosinophil and mast cell infiltration in the lung tissues of mice treated with MN-Ova + CpG, and low deposition of mucus inside their lung bronchioles. Overall, coated MNs ameliorated the symptoms of airway allergy in mice similar to SCIT and could provide a novel means of painless allergen-specific immunotherapy.

Original languageEnglish
Pages (from-to)3033-3042
Number of pages10
JournalMolecular Pharmaceutics
Issue number8
StatePublished - Aug 3 2020


  • allergen immunotherapy
  • allergy treatment
  • cutaneous allergen immunotherapy
  • microneedles
  • ovalbumin-induced allergy
  • subcutaneous allergen-specific immunotherapy


Dive into the research topics of 'Microneedle-Mediated Allergen-Specific Immunotherapy for the Treatment of Airway Allergy in Mice'. Together they form a unique fingerprint.

Cite this